We have located links that may give you full text access.
Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy.
Journal of Dermatological Treatment 2018 November 29
BACKGROUND: Psoriasis is a common chronic and immune-mediated inflammatory skin disease.
OBJECTIVES: This study aimed to investigate the serum levels of Chitinase-3-like protein 1 (YKL-40) in patients with psoriasis vulgaris before and after narrow-band ultraviolet B (NB-UVB) phototherapy.
METHODS: This study was designed as a cross-sectional case-control. This study included 30 patients with psoriasis vulgaris and 20 healthy individuals. Psoriasis Area and Severity Index (PASI) score were used to evaluate the patients with psoriasis vulgaris before and after treatment. All patients were treated 2 times per week for 3 months with NB-UVB phototherapy. Enzyme-linked immunosorbent assay (ELISA) was used to assess serum levels of YKL-40 of the healthy control subjects and psoriatic patients before and after treatment by NB-UVB phototherapy.
RESULTS: The serum level of YKL-40 was significantly higher in patients with psoriasis vulgaris versus healthy control subjects (p value<.001). There were significant reductions in the serum levels of YKL-40 and PASI scores after 3 months of treatment with NB-UVB phototherapy in patients with psoriasis vulgaris (p value<.001).
CONCLUSIONS: This study concluded that NB-UVB phototherapy for three months in patients with psoriasis vulgaris was an essential method for decreasing the serum levels of YKL-40 and PASI scores.
OBJECTIVES: This study aimed to investigate the serum levels of Chitinase-3-like protein 1 (YKL-40) in patients with psoriasis vulgaris before and after narrow-band ultraviolet B (NB-UVB) phototherapy.
METHODS: This study was designed as a cross-sectional case-control. This study included 30 patients with psoriasis vulgaris and 20 healthy individuals. Psoriasis Area and Severity Index (PASI) score were used to evaluate the patients with psoriasis vulgaris before and after treatment. All patients were treated 2 times per week for 3 months with NB-UVB phototherapy. Enzyme-linked immunosorbent assay (ELISA) was used to assess serum levels of YKL-40 of the healthy control subjects and psoriatic patients before and after treatment by NB-UVB phototherapy.
RESULTS: The serum level of YKL-40 was significantly higher in patients with psoriasis vulgaris versus healthy control subjects (p value<.001). There were significant reductions in the serum levels of YKL-40 and PASI scores after 3 months of treatment with NB-UVB phototherapy in patients with psoriasis vulgaris (p value<.001).
CONCLUSIONS: This study concluded that NB-UVB phototherapy for three months in patients with psoriasis vulgaris was an essential method for decreasing the serum levels of YKL-40 and PASI scores.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app